#China #Shanghai #AI-STAL #Sanyou Biopharmaceuticals #Shanghai Municipal

Sanyou Biopharmaceuticals Achieves Milestone Recognition

Sanyou Biopharmaceuticals, a prominent player in the biopharmaceutical industry, has officially been designated as a "Shanghai Municipal Enterprise Technology Center." This accolade underscores the company's remarkable technological innovation capabilities, robust research and development (R&D) infrastructure, and consistent investment in pioneering innovations. Such recognition serves not only as evidence of Sanyou's excellence in technology commercialization but also as a testament to its leadership in the industry.

The designation as a municipal technology center does not come as a surprise, given Sanyou's unwavering dedication to innovation and high-quality development since its inception. The company's mission, "making innovative biologics R&D easy for clients worldwide,” is evidenced by their AI-driven Super Trillion Antibody Library (AI-STAL), which functions as a core engine, complemented by a state-of-the-art integrated wet-dry laboratory platform. This innovative framework enables Sanyou to tackle complex challenges in drug molecule generation and screening effectively.

To date, Sanyou has successfully powered over 1,200 new drug development initiatives, collaborating with more than 2,000 pharmaceutical and biotechnology companies globally. This extensive network showcases the company's commitment to fostering innovation across the biopharmaceutical ecosystem. Over the years, Sanyou has continually reinvested in its R&D efforts, refining its innovation framework, attracting top-tier research talent, and building a systematic platform dedicated to research, experimentation, and technology transfer.

Sanyou's recognition as a technology center comes along with a wealth of prestigious certifications attained throughout its journey. These credentials not only confirm Sanyou's compliance with industry standards but also reflect its robust capabilities in various domains:

• - In December 2022, the company was certified as a National High-Tech Enterprise, marking its entry into the national innovation tier.
• - In January 2023, Sanyou received accolades as an Innovative Small and Medium Enterprise at the district level, demonstrating regional innovation vitality.
• - Following this, in February, Sanyou was named a Star of Shanghai Zhangjiang for potential enterprises, signifying targeted cultivation from Shanghai's core area for scientific and technological innovation.
• - By March 2023, the company had also been awarded the title of Shanghai Specialized, Refined, Distinctive, and Innovative SME, indicating its competitive advantages in specialized development.
• - In September 2023, Sanyou secured ISO9001 Quality Control System certification, which emphasized its commitment to providing standardized products and services.

Continuing its upward trajectory, in October 2023, Sanyou became recognized as an Enterprise Technology Center at the Xuhui District, laying the groundwork for standardizing enterprise technological platforms. Later, it was designated as a Shanghai Science and Technology Little Giant Cultivation Enterprise in November, further solidifying its position as a technology leader. In January 2026, the company reached a significant milestone by advancing to a Shanghai Municipal Enterprise Technology Center, affirming its R&D system and innovation mechanisms as being among the city’s leading frameworks.

These achievements highlight Sanyou's philosophy of "Quality, Speed, Innovation," which resonates in the firm's long-term vision of developing a powerful engine for original new drugs. As a front-runner in biopharmaceutical R&D, Sanyou is poised to continue leveraging its AI-powered Super Trillion Antibody Library to accelerate global drug discovery and deeply engage with target research. The company aims to play a pivotal role in the industry’s technological transformation, driving future developments and contributing uniquely Chinese insights and strengths to global healthcare advancements.

About Sanyou Biopharmaceuticals

Founded in Shanghai, Sanyou Biopharmaceuticals operates on the principle of simplifying innovative biologics R&D for clients around the globe. The firm focuses on crucial challenges faced at the source of innovative drug development. Sanyou's AI-STAL, together with a fully integrated R&D platform, provides end-to-end solutions for drug discovery, particularly concerning molecular discovery and selection.

With business centers established across Asia, North America, and Europe, Sanyou is committed to creating a seamless international network within the biopharmaceutical landscape. It has completed several collaborations, leading to over 50 projects, of which more than ten have progressed to IND approval and clinical development phases. Moreover, Sanyou is proud of its substantial intellectual property portfolio, comprising over 170 filed invention patents, securing more than 30 of them, and numerous certifications, including the esteemed National High-Tech Enterprise status.

As it continues to expand its research and development capabilities, Sanyou Biopharmaceuticals remains focused on innovation and collaborative partnerships to accelerate new therapeutic developments worldwide.